Therapeutic targetable fusion genes in ovarian carcinoma
Project/Area Number |
16H06267
|
Research Category |
Grant-in-Aid for Young Scientists (A)
|
Allocation Type | Single-year Grants |
Research Field |
Obstetrics and gynecology
|
Research Institution | Niigata University |
Principal Investigator |
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2018: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2017: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2016: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
Keywords | 融合遺伝子 / トランスレーショナルリサーチ / ゲノム医学 / 卵巣癌 / 腫瘍免疫 |
Outline of Final Research Achievements |
The frequency and function of fusion genes in ovarian cancer remained unclear. Our aim of this study was to identify fusion genes in ovarian cancer through RNA sequencing data analysis and to clarify clinical significance of fusion genes in ovarian cancer. We performed RNA sequencing for 57 ovarian clear cell carcinoma samples and detected fusion genes based on our PRADA algorithm. Of 57 samples, ten harbored at least one therapeutically targetable fusion gene such as kinase fusion genes. In addition, 18 samples had at least one fusion gene which might be recognized as a neoantigen by host. In conclusion, gene fusion was one of important genomic alterations in clinical field as well as tumorigenesis.
|
Academic Significance and Societal Importance of the Research Achievements |
卵巣明細胞癌は日本人に多い組織型で、標準的な抗がん剤が効きにくいことが知られている。本研究では、卵巣明細胞癌の融合遺伝子プロファイルを同定することによって、新たな治療標的を同定することができ、今後の分子標的薬の開発につながる可能性がある。また融合遺伝子をneoantigenとしてとらえることで、腫瘍免疫においても、免疫チェックポイント阻害薬の有望な分子マーカーになり、高額な免疫チェックポイント阻害薬による治療対象を最適化することができる可能性があり、医療経済的にも重要な研究成果と言える。
|
Report
(4 results)
Research Products
(23 results)
-
-
-
-
-
[Journal Article] Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions2018
Author(s)
Tamura R, Yoshihara K, Saito T, Ishimura R, Martinez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda K, Sato S, Itamochi H, Motoyama T, Aoki Y, Okuda S, Casingal CR, Nakaoka H, Inoue I, Verhaak RGW, Komatsu M, Enomoto T.
-
Journal Title
Oncogenesis
Volume: 7
Issue: 1
Pages: 4-4
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] The impact of stromal Hic-5 on the tumorigenesis of colorectal cancer through lysyl oxidase induction and stromal remodeling.2018
Author(s)
Omoto T, Kim-Kaneyama JR, Lei XF, Orimo A, Ohnishi K, Yoshihara K, Miyauchi A, Li S, Gao L, Umemoto T, Tanaka J, Nakahara K, Takeya M, Ishida F, Kudo SE, Haraguchi S, Miyazaki T, Miyazaki A.
-
Journal Title
Oncogene.
Volume: 37
Issue: 9
Pages: 1205-1219
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
[Journal Article] Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.2017
Author(s)
Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T.
-
Journal Title
British Journal of Cancer
Volume: 117
Issue: 5
Pages: 717-724
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.2017
Author(s)
Yamawaki K, Ishiguro T, Mori Y, Yoshihara K, Suda K, Tamura R, Yamaguchi M, Sekine M, Kashima K, Higuchi M, Fujii M, Okamoto K, Enomoto T
-
Journal Title
Cancer Sci.
Volume: 108
Issue: 4
Pages: 632-640
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-